B-Type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis by Stefanović-Nešković, Jelena et al.
J Med Biochem 2018; 37 (4) DOI: 10.1515/jomb-2017-0058
UDK 577.1 : 61                         ISSN 1452-8258
J Med Biochem 37: 406–414, 2018 Original paper
Originalni nau~ni rad
B-TYPE NATRIURETIC PEPTIDE AS A MARKER OF DIFFERENT 
FORMS OF SYSTEMIC SCLEROSIS
B-TIP NATRIURETSKOG PEPTIDA KAO MARKER 
RAZLI^ITIH OBLIKA SISTEMSKE SKLEROZE
Jelena Stefanovi} Ne{kovi}1, An|elka Risti}2, Milan Petronijevi}3, Aleksandra Zeljkovi}4, 
Aleksandra Grdini}5, Ognjen Gudelj1, Branka \urovi}6, Branimir Ne{kovi}7
1Clinic for Cardiology, Military Medical Academy, Belgrade, Serbia
2Clinic for Emergency and Internal Medicine, Military Medical Academy, Belgrade, Serbia
3Clinic for Rheumatology, Military Medical Academy, Belgrade, Serbia
4Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade
5University Hospital Northern Norway, Medical Department, Norway
6Institute of Occupational Medicine, Medical Academy, Belgrade, Serbia
7Clinic for General Surgery, Military Medical Academy, Belgrade, Serbia
Address for correspondence:
Jelena Stefanovi} Ne{kovi}
Ul. Vojvode Vlahovi}a 41B, Zvezdara, Beograd
Mob: 063 1899499
e-mail: stefanovic.jelena1ªgmail.com
Summary 
Background: Systemic sclerosis (SSc) is an autoimmune
connective tissue disease which affects various tissues and
organs, including skin, lungs, kidneys, gastrointestinal tract
and cardiovascular system. Cardiac involvement is the most
commonly recognized problem and a significant cause of
morbidity. The brain natriuretic peptide (BNP) is a previous-
ly known marker of elevated cardiovascular risk in SSc, but
the levels of BNP in various forms of SSc have not been
investigated so far. 
Aim: The aim of our study was to evaluate the influence of
SSc on the function of the right ventricle and the right atri-
um using the echocardiographic parameters. Moreover, we
examined the levels of BNP in different forms of SSc as well
as the association of disease severity with the plasma con-
centrations of BNP. 
Methods: We included 42 patients with newly diagnosed
SSc and patients whose disease had been diagnosed earli-
er. SSc patients and non-SSc control patients were exam-
ined by using echocardiography and the concentrations of
BNP were determined. 
Results: We analyzed differences in the parameters of right
ventricle (RV) function and right atrium (RA) function
between SSc patients and healthy controls. The two groups
Kratak sadr`aj
Uvod: Sistemska skleroza (SSc) jeste autoimuna bolest ve -
zivnog tkiva koja uti~e na razli~ita tkiva i organe, uklju~uju}i
ko`u, plu}a, bubrege, gastrointestinalni trakt i kardiovasku-
larni sistem. Komplikacije na srcu su naj~e{}e prepoznat
problem i zna~ajan uzrok morbiditeta. Mo`dani natriuretski
peptid (BNP) odranije je poznat marker povi{enog kardio -
vaskularnog rizika u SSc, ali nivoi BNP-a u razli~itim for -
mama SSc do sada nisu ispitivani. 
Cilj: Cilj na{e studije bio je proveriti uticaj SSc na funkciju
desne komore i desne pretkomore pra}enjem ehokardio -
graf skih parametara. Tako|e, ispitivali smo koncentracije
BNP-a u razli~itim formama SSc. 
Metode: U studiju je uklju~eno 42 bolesnika sa novo otkri -
venom SSc, kao i bolesnici kod kojih je bolest ranije dijag-
nostikovana. Bolesnicima sa SSc i kontrolnoj grupi obavljen
je ultrazvu~ni pregled srca i odre|ena koncentracija BNP-a. 
Rezultati: Analizirali smo razlike u parametrima funkcija
desne komore i desne pretkomore izme|u bolesnika sa SSc
i zdravih osoba. Zadebljanje zida desne komore je ve}e kod
bolesnika sa SSc (p<0,001), dok se povr{ine desne
komore u sistoli (RVESA; p=0,408) i dijastoli (RVEDA;
p=0,368) ne razlikuju me|u ispitanicima. Nasuprot tome,
veli~ina desne pretkomore – kratke ose na kraju dijastole
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Introduction
Systemic sclerosis (SSc) is an autoimmune con-
nective tissue disease which affects various tissues
and organs, including skin, lungs, kidneys, gastroin-
testinal tract and cardiovascular system (1). There are
two subtypes of SSc, i.e., diffuse cutaneous SSc (skin
thickening also involves the extremities proximal to
elbows and knees, chest, abdomen and back) and
limited cutaneous SSc (skin thickening is localized to
the face, neck and extremities distal to elbows and
knees) (2). Cardiac involvement is the most common-
ly recognized problem and a significant cause of mor-
bidity (3). The presence of cardiac events is a bad
prognostic sign and is one of the leading causes of
mortality in patients with SSc (4–6). The brain natri-
uretic peptide (BNP) is a previously known marker of
elevated cardiovascular risk in SSc, but the levels of
BNP in various forms of SSc have not been investigat-
ed so far.
Cardiac involvement can be primary and sec-
ondary. Primary cardiac involvement, which develops
as a direct consequence of SSc, may manifest as
myocardial involvement, fibrosis of the conduction
system, pericardial and less frequently, as valvular dis-
ease (2). Secondary cardiac involvement may mani-
fest as a consequence of pulmonary arterial hyperten-
sion (PAH), interstitial lung disease and kidney
disease (7, 8).
For the detection of myocardial damage in
patients with SSc, in everyday clinical work a large
number of noninvasive methods is used, but the most
accessible are electrocardiography and echo cardio -
graphy (9, 10). For many years, the right ventricle
(RV) has been considered less relevant in cardiac dis-
eases than the left ventricle (11). Nowadays, it is con-
sidered that the RV function markers can be used for
management and prognosis of many cardiac dis-
eases, such as congestive heart failure, arrhyth mia
and sudden cardiac death (12, 13). Echocardio -
graphy is an available, noninvasive technique, less
expensive than the other techniques and is used for
evaluation of RV function. Upon the recommendation
of The Euro pean Heart Association, echocardiogra-
phy should be done annually for asymptomatic SSc
patients and patients with symptomatic connective tis-
sue disease (14).
The role of clinical chemistry laboratory in diag-
nosis and monitoring of SSc is largely underestimat-
ed. However, recently brain natriuretic peptide (BNP)
and N-terminal proBNP (NT-proBNP) were proposed
as the latest useful markers in the prediction of car-
diovascular outcome in SSc (15–17). Brain natriuretic
peptide (BNP) is a natriuretic hormone that is initially
identified in the brain but released primarily from the
heart, in particular the ventricles.
Recent studies suggest that the functions of the
right and left ventricle have been reduced in SSc
patients and they are associated with morbidity. It has
been proven that measurements of the systolic func-
tion of the right ventricle, such as the mobility of the
tricuspid annular plane systolic excursion (TAPSE),
the right ventricle fractional area change (FAC), an
indicator of RV myocardial contractility via the TEI
index, S wave, correlate with reduced survival. It is
known that an enlarged right atrium and right ventri-
cle in SSc patients are directly related to the symp-
had similar distribution of gender, but SSc patients were
significantly older than controls. RV wall thickness was
increased in SSc patients (p<0.001), while right ventricular
end-systolic area (RVESA; p=0.408) and right ventricular
end-diastolic area (RVEDA; p=0.368) did not differ among
the examinees. In contrast, RA minor-axis dimension
(p=0.001) and the tricuspid annular plane systolic excur-
sion (TAPSE) (p=0.001) were significantly higher in SSc
patients. Also, we analyzed differences in brain natriuretic
peptide (BNP) concentrations between diffuse cutaneous
systemic sclerosis (DSSc) and limited cutaneous systemic
sclerosis (LSSc) patients. DSSc patients had significantly
higher concentrations of BNP. We found that levels of BNP
were in significant positive correlations with age
(p=0.007), disease duration (p=0.023), C reactive protein
(CRP) (p=0.032), right ventricle fractional area change
(FAC) (p=0.022), pulmonary vascular resistance (PVR)
and Rodnan score (p=0.019). 
Conclusions: Given the obtained results, the laboratory
determination of BNP could be useful in differentiating dif-
ferent forms of systemic sclerosis as well as in predicting
the severity of the disease and future cardiovascular com-
plications.
Keywords: systemic sclerosis, right ventricle, right atrium,
brain natriuretic peptide (BNP), capillaroscopy, Rodnan
score
(p=0,001) i sistolni pomak lateralnog dela trikuspidnog
prstena prema vrhu srca (TAPSE) (p=0,001) zna~ajno su
ve}i kod bolesnika sa SSc. Tako|e, analizirali smo razlike u
koncentraciji BNP-a izme|u bolesnika sa difuznom sistem -
skom sklerozom (DSSc) i lokalizovanom sistemskom skle ro -
zom (LSSc). DSSc bo les nici su imali zna~ajno ve}e kon -
centracije BNP-a. Nivo BNP-a bio je u zna~ajnoj po zitivnoj
ko relaciji sa staro{}u (p=0,007), trajanjem bolesti (p=0,023),
C reak tiv nim proteinom (CRP) (p=0,032), frakcionim
skra }e njem desne komore (FAC) (p=0,022), plu}nom
vaskularnom re zistencijom (PVR) (p=0,042) i Rodnan
skorom (p=0,019). 
Zaklju~ak: S obzirom na dobijene rezultate, laboratorijsko
odre|ivanje BNP-a moglo bi biti korisno u diferencijaciji
raz li~itih oblika sistemske skleroze, kao i u predvi|anju te -
`ine bolesti i budu}ih kardiovaskularnih komplikacija.
Klju~ne re~i: sistemska skleroza, desna komora, desna
pretkomora, BNP, kapilaroskopija, Rodnan skor
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toms and the signs of heart failure and mortality. The
right atrium size is correlated with the cardiac involve-
ment in pulmonary arterial hypertension (PAH) (4–6,
9). Yet, it is still unclear whether BNP has any po -
tential in clustering patients according to the form
and severity of SSc.
The aim of our study was to evaluate the influ-
ence of SSc on the function of the right ventricle and
right atrium using the echocardiographic parameters.
Moreover, we examined the levels of BNP in different
forms of SSc as well as the association of disease
severity with the BNP plasma concentration.
Materials and Methods
We included 42 patients with the newly diag-
nosed SSc and patients whose disease had been diag-
nosed earlier. The testing was conducted in the Clinic
for Emergency Internal Medicine and Clinic for Rheu -
matology of the Military Medical Academy in 2016. A
total of 42 patients with SSc were diagnosed as SSc
according to the American College of Rheumatology
(ACR) classification criteria for SSc (18). The exclu-
sion criteria were asthma, chronic obstructive bron-
chitis, patients without known cardiovascular and pul-
monary disease.
SSc patients and non-SSc control patients were
examined by using echocardiography performed by a
single cardiologist. Conventional echocardiographic
examinations were performed using a Phillips iE-33
system. All parameters were measured according to
the published recommendations.
The following parameters were investigated: 
– Measurement of the RV dimensions: RV wall
thickness, right ventricular end-systolic area
(RVESA) and right ventricular end-diastolic area
(RVEDA) and 2D fractional area change (FAC),
– Analysis of blood flow through the tricuspid
valve during diastole: early diastolic filling veloc-
ity (Etz), late diastolic filling velocity (Atz), Etz to
Atz ratio, deceleration time (DT),
– TAPSE (the tricuspid annular plane systolic
excur sion), right ventricular systolic pressure
(RVSP) based on peak tricuspid regurgitant
velocity (TRVmax), 
– Inferior vena cava diameter (VCI). 
– Pulmonary vascular resistance (PVR) was nonin-
vasively estimated utilizing the Abbas equation:
(tricuspid regurgitant velocity/ time velocity inte-
gral of the RV outflow tract×10+0.16) with an
abnormal value defined as > 2.0 Wood Units
(WU) (19).
– The tricuspid annular velocities were determined
by pulsed wave Doppler tissue: peak early ve -
locity (e’), peak late diastolic velocity (a’), e’/a’
ratio, the ratio of early diastolic tricuspid inflow
to tricuspid lateral annular velocity (tricuspid
Etz/e'), velocity of the tricuspid annular systolic
motion (s’).
– The TEI index or myocardial performance index
(MPI) is an indicator of RV myocardial contrac-
tility. It is defined as the ratio of total isovolumic
time divided by ejection time (ET) (19). It is cal -
cu lated using the following formula: MPI=(IVRT
+IVCT)/ET.
Capillaroscopy is a simple, safe and painless
method for evaluating small vessels of the microcircu-
lation (20). The importance of capillaroscopy as a
noninvasive diagnostic method is in early detection of
abnormalities in capillary morphology, monitoring the
progression of systemic disease and involvement of
internal organs. The abnormalities can be observed
long before the onset of clinical symptoms (21). In
most SSc patients, peripheral microangiopathy fol-
lows a typical scleroderma pattern, consisting of
‘early’, ‘active’ and ‘late’ phases (22). The »early«
pattern can be detected many years before the com-
plete clinical manifestation of SSc, and the progres-
sion to »active« and »late« patterns corresponds to
internal organ involvement (23). Capillaroscopy as a
diagnostic method is significant because it is included
in the EULAR classification criteria of SSc (24). 
Plasma levels of BNP were determined by a
commercially available immunoassay on an automat-
ed platform (ADVIA Centaur BNP assay; Siemens
Health care Diagnostics Inc, Tarrytown, NY, USA). The
Advia Centaur BNP assay measures BNP concentra-
tions up to 5000 pg/mL (1445 pmol/L) with a mini-
mum detectable concentration (analytical sensitivity)
of < 2.0 pg/mL (0.58 pmol). The functional sensitiv-
ity is defined as the lowest BNP concentration deter-
mined at a coefficient of variation of 20%. The ADVIA
Centaur BNP assay functional sensitivity was deter-
mined to be 2.5 pg/mL (0.72 pmol/L). The intra-
assay coefficient of variation is 4.3% »within-run« and
1.9% »run-to-run« at 29.4 pg/mL, 2.5% »within-run«
and 2.1% »run-to-run« at 48.5 pg/mL, 1.8% »within-
run« and 1.9% »run-to-run« at 410 pg/mL, 2.0%
»within-run« and 1.5% »run-to-run« at 458 pg/mL,
2.0% »within-run« and 0.5% »run-to-run« at 1452
pg/mL and 2.1% »within-run« and 1.7% »run-to-run«
at 1736 pg/mL. A reference range for BNP is defined
as the interval between 2.00 and 32.80 pg/mL.
The modified Rodnan skin score (MRSS) is a
measure of skin thickness and measure of disease
severity and mortality in patients with dcSSc (25). An
increase in skin thickening is associated with in -
creased risk of the internal organs’ involvement and
increased mortality (26).
This observational cross-sectional study was
approved by the Ethics Committee of the Institutional
Review Board (IRB) of the Military Medical Academy
and written informed consent was given by the
patients. This study complies with the World Medical
Association’s Declaration of Helsinki.
Statistical analysis
Variables that followed normal distribution were
presented as mean ± standard deviation (Sd) and
compared by the Student-t test or ANOVA. Asym -
metrically distributed variables were presented as
median (interquartile range) and analyzed by Mann-
Whitney U-test. Chi-square test – contingency tables
were employed for analysis of categorical variables,
presented as absolute frequencies. Correlation analy-
sis was performed by using Spearman’s test.
Differences with P<0.05 were considered to be sta-
tistically significant. Exploration of differences in BNP
levels among patients divided according to the results
of capillaroscopy was done by the Kruskal-Wallis test
following post hoc Mann-Whitney U-test. The Bon -
ferroni correction was used in order to reduce a like-
lihood of type I error. According to the Bonferroni
adjustment, statistical significance for multiple com-
parison testing was set at P<0.017. All statistical
analyses were done by employing PASW Statistics ver-
sion 18.0 and MedCalc Software version 11.4. 
Results
In this study, we included 42 patients with SSc
aged 34–71 years (mean: 51.52; Sd: 10.63) and 40
non-SSc control patients aged 21–62 years (mean:
39.40; Sd: 9.95) without known cardiovascular and
pulmonary disease. SSc patients were predominantly
women. Six patients were men and 36 were women.
In Table I, we presented the results of analysis of
differences in parameters of RV function between SSc
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Table I Parameters of right ventricular function in SSc patients and healthy controls.
SSc (n=42) Controls (n=40) P
Age (years) 51.52 ± 10.63 39.40 ± 9.95 <0.001
Gender, male (n) 6 11 0.177
RV wall thickness (cm)# 0.40 (0.40–0.51) 0.35 (0.30–0.98) <0.001
RVESA (mm) 5.55 (4.50–8.25) 5.90 (4.38–6.90) 0.408
RVEDA (mm) 10.50 (9.23–13.53) 12.20 (9.40–13.08) 0.368
FAC (%) 49.15 ± 12.87 48.80 ± 8.82 0.888
RA major-axis dimension (cm) 4.45 ± 0.56 4.33 ± 0.49 0.295
RA minor-axis dimension (cm) 3.48 ± 0.42 3.19 ± 0.36 0.001
TAPSE (cm) 2.47 ± 0.39 2.21 ± 0.33 0.001
Etz (cm/s)
# 55.90 (46.90–59.55) 56.80 (53.88–62.40) 0.021
Atz (cm/s)
# 38.00 (35.08–39.83) 44.25 (41.53–49.53) <0.001
Etz/Atz
# 1.40 (1.30–1.70) 1.30 (1.14–1.38) 0.001
Etz/e’
# 5.20 (4.19–6.35) 4.60 (4.10–4.90) 0.017
s’ (cm/s) # 12.90 (11.48–15.70) 12.00 (11.33–12.68) 0.007
e’ (cm/s) # 10.80 (8.19–14.18) 12.10 (10.53–12.70) 0.148
a’ (cm/s) # 13.20 (11.85–15.80) 9.35 (8.70–10.10) <0.001
e’/a’# 0.70 (0.50–0.95) 1.10 (0.90–1.30) <0.001
DT (ms) # 193.00 (159.50–232.00) 204.50 (160.00–216.75) 0.981
TR Vmax (cm/s) # 2.51 (2.13–2.78) 2.02 (1.76–2.32) 0.001
RVSP (mm Hg) 33.51 ± 8.71 28.80 ± 4.42 0.003
VCI (cm) # 1.50 (1.13–1.70) 1.19 (1.02–1.56) 0.005
PVR (MPa×s/m3)# 1.56 (1.28–1.99) 1.22 (1.14–1.30) <0.001
TEI index# 0.40 (0.30–0.43) 0.30 (0.30–0.40) 0.090
Data are presented as mean ± Sd for continuous variables, or as absolute frequencies for categorical variables and compared
by the Student’s t-test or by the Chi-square test, respectively. #Due to asymmetrical distribution, values are presented as medi-
an (interquartile range) and analyzed by the Mann-Whitney U-test.
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patients and healthy controls. The two groups had
similar distribution of gender, but patients were signif-
icantly older than controls. RV wall thickness was
increased in patients, while RVESA and RVEDA did not
differ among the examinees. Similarly, we found no
differences in the FAC, RA major-axis dimension and
Etz. In contrast, RA minor-axis dimension and TAPSE
were significantly higher in SSc patients. Etz/Atz ratio,
Etz/e’ratio, s’ velocity and a’ velocity were significantly
higher, while Etz, Atz and e’/a’ratio were lower in SSc
patients than in controls. We found no differences in
DT and TEI index, but TR Vmax, VCI, RVSP and PVR
were significantly higher in SSc patients. 
In addition, we compared the same parameters
as in the previous analysis among limited cutaneous
systemic sclerosis (LSSc) and diffuse cutaneous sys-
temic sclerosis (DSSc) patients (Table II). Apart from
the expected gender differences, all the other exam-
ined parameters were uniform between the two
groups of SSc patients, with the exception of the e’/a’
ratio which was significantly higher in LSSc patients.
Next, we analyzed differences in the concentra-
tions of the brain natriuretic peptide (BNP) between
DSSc and LSSc patients. As it can be seen in the
Figure 1, DSSc patients had significantly higher con-
centrations of the BNP.
Based on the previous findings, we further
explored the levels of BNP in SSc patients clustered
by the results of capillaroscopy (Figure 2). The
obtained results revealed that SSc patients with an
early form of the disease had the lowest concentra-
tions of BNP, whereas the levels of this marker
increased in parallel with the disease progression.
The patients with an early form of SSc had markedly
lower concentrations of BNP than subjects with a late
Table II Parameters of right ventricular function in DSSc and LSSc patients.
DSSc (n=17) LSSc (n=25) P
Age (years) 52.06 ± 9.52 51.16 ± 11.51 0.792
Gender, male (n) 6 0 0.002
RV wall thickness (cm)# 0.40 (0.38–0.53) 0.40 (0.40–0.55) 0.252
RVESA (mm) 5.60 (4.55–8.15) 5.50 (4.46–8.30) 0.635
RVEDA (mm) 10.10 (9.01–15.00) 10.70 (9.50–13.30) 0.808
FAC (%) 49.82 ± 11.61 48.67 ± 13.92 0.781
RA major–axis dimension 4.45 ± 0.62 4.45 ± 0.54 0.978
RA minor–axis dimension 3.52 ± 0.34 3.45 ± 0.47 0.606
TAPSE (cm) 2.44 ± 0.47 2.49 ± 0.33 0.670
Etz (cm/s)
# 51.40 (46.40–58.65) 56.80 (47.70–62.70) 0.159
Atz (cm/s)
# 38.20 (35.10–45.05) 38.00 (35.00–39.00) 0.450
Etz/Atz
# 1.40 (1.30–1.57) 1.50 (1.25–1.70) 0.660
Etz/e’
# 5.77 (4.45–6.70) 5.20 (3.53–5.85) 0.299
s’ (cm/s) # 12.80 (10.99–16.25) 13.20 (11.85–15.40) 0.710
e’ (cm/s) # 9.80 (8.05–11.95) 11.60 (8.44–16.15) 0.187
a’ (cm/s) # 13.90 (12.25–16.55) 12.80 (11.50–15.10) 0.270
e’/a’# 0.60 (0.49–0.70) 0.88 (0.55–1.23) 0.008
DT (ms) # 201.00 (155.50–245.00) 187.00 (159.00–232.00) 0.682
TR Vmax (cm/s) # 2.57 (2.10–3.27) 2.50 (1.16–1.75) 0.346
RVSP (mm Hg) 33.06 ± 10.08 33.82 ± 7.85 0.786
VCI (cm) # 1.60 (1.40–1.70) 1.50 (1.15–1.75) 0.554
PVR (MPa·s/m3)# 1.56 (1.32–17.16) 1.46 (1.26–1.76) 0.150
TEI index# 0.30 (0.30–0.45) 0.40 (0.30–0.45) 0.559
Data are presented as mean ± Sd for continuous variables, or as absolute frequencies for categorical variables and compared
by the Student’s t-test or by the Chi-square test, respectively. #Due to asymmetrical distribution, values are presented as medi-
an (interquartile range) and analyzed by the Mann-Whitney U-test.
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form, although with borderline significance (reached
P=0.020 vs. P<0.017 according to Bon ferroni adjust -
ment). In order to explore whether the increase in
BNP levels arises as a consequence of older age, we
analysed the age differences between patients with
the various forms of SSc. Our results have shown
that there are no statistically significant differences
among the observed groups of the patients with an
early, active and late form of SSc (52.00±12.49
vs. 50.04±10.72 vs. 54.27±9.38 respectively,
P=0.561).
We found that levels of BNP were in significant
positive correlations with age, disease duration, C
reactive protein (CRP), fractional area change (FAC),
pulmonary vascular resistance (PVR) and Rodnan
score, while in negative correlation with e’/a’ ratio.
Discussion
Cardiac involvement in SSc may be presented
with various manifestations and is an indicator of a
poor prognosis (2). Recent studies have suggested
that the RV and left ventricle (LV) functions are
reduced in patients with SSc and are associated with
elevated morbidity (27–29). In our study, we com-
pared the examined parameters of RV systolic func-
tion in SSc patients and healthy controls. Our results
confirmed the previous findings, when it came to the
RV wall thickness. Although in both groups the RV
had an average wall thickness, the RV wall thickness
was significantly higher in SSc patients. Right ventric-
ular end-systolic area (RVESA) and right ventricular
end-diastolic area (RVEDA) did not differ among the
examinees. We found no differences in the FAC.
TAPSE were significantly higher in SSc patients. There
were no differences in TEI index among the exami-
nees. s’ velocity was significantly higher in SSc
patients than in healthy controls (Table I).
It has been proved that measures of RV systolic
function such as TAPSE, S  velocity, FAC, and TEI in dex
correlate with decreased survival (27, 29). In our
study, we found no differences in the FAC and TEI in -
dex, while TAPSE and s’ velocity were significantly high-
er in SSc patients than in healthy controls (Table I).
Parameters of the RV diastolic dysfunction are
the Etz/Atz ratio, DT, the Etz/e’ ratio, and RA size. In
our study, we investigated all these parameters. We
found no differences in the RA major-axis dimension.
In contrast, RA minor-axis dimensions were signifi-
cantly higher in SSc patients. The Etz, Atz and e’/a’
ratio were lower in SSc patients than in controls, while
Etz/Atz ratio, Etz/e’ratio, and a’ velocity were signifi-
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Figure 1 Concentrations of the brain natriuretic peptide
(BNP) in DSSc and LSSc patients.
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Figure 2 Concentrations of the brain natriuretic peptide
(BNP) in SSc patients clustered by the results of capillaro -
scopy.
Data are compared by Kruskal-Wallis test, followed by post
hoc Mann-Whitney U-test. Statistically significant differences
were considered if P<0.017, according to Bonferroni correc-
tion.
*P=0.020 for differences between early and late form of
SSc.
Table III Correlations of BNP with other examined parame-
ters in patients with SSc.
Spearman’s 
correlation coefficient P
Age (years) 0.417 0.007
Disease duration 0.358 0.023
CRP (mg/L) 0.348 0.032
FAC (%) 0.366 0.022
e’/a’ -0.389 0.013
PVR (MPa×s/m3) 0.323 0.042
Rodnan score 0.368 0.019
cantly higher. We found no differences in DT and e’
velocity (Table I). It is known that the right atrial and
RV chamber enlargement in SSc are directly related
with the heart failure symptoms and mortality (30–
37). RA size is correlated with clinical outcomes in
PAH (28). In our SSc population, the Etz/Atz ratio was
significantly higher than in healthy controls (Table I).
This can be considered as an index of abnormal right
ventricular relaxation. Another explanation is that it is
an indicator of diastolic dysfunction, which is a more
subtle disorder and occurs earlier.
Our results have not shown a correlation of the
disease severity with the echocardiogram assessment
of systolic function of the RV, which is not in accor-
dance with the results of previous studies. In our
study, RVSP and PVR were significantly higher in SSc
patients, although values  were in the normal range.
This can be explained as an increased risk in these
patients for the occurrence of PAH.
In a recent study, it has been shown that non -
invasive measurements of PVR predict pulmonary
arterial hypertension (PAH) in SSc (19). Guazzi et al.
(32) reported that the TAPSE/systolic pulmonary
artery pressure (SPAP) ratio improves the prognostic
risk stratification in heart failure patients when com-
pared to TAPSE alone and a ratio, 0.36 mm/mmHg
predicts higher mortality in such patients (32). The
inferior vena cava was significantly higher in SSc
patients. It is known that dilated IVC usually denotes
elevated RA pressures, and the results in our study
could be explained by the fact that the SSc patients
have a higher risk for PAH.
In the next step, we compared parameters of RV
function among subjects with limited and diffuse
forms of scleroderma (Table II). According to our
results, echocardiographic parameters were similar in
SSc patients and healthy controls (38–40). Some
studies have found that cardiac manifestations occur
in both diffuse and limited cutaneous forms of SSc,
whereas according to others, the prevalence is greater
in the diffuse cutaneous form of the disease and the
DSSc is associated with significant morbidity and mor-
tality (2, 41). 
Although echocardiographic markers failed to
detect significant differences between DSSc and LSSc
participants in our study, DSSc patients had signifi-
cantly higher concentrations of BNP (Figure 1).
Increased concentration of natriuretic peptides in the
plasma may be associated with an increased risk of
pulmonary hypertension, which arises as a conse-
quence of RV dysfunction (37, 39). It has been pre -
viously demonstrated (15–17) that BNP might be
useful in predicting cardiovascular outcome in SSc
patients. In this study, we demonstrated that the lab-
oratory determination of BNP can also be used as a
tool in differentiating various types of SSc. Further -
more, considering that the parameters of RV did not
differ between the two forms of SSc in our study
(Table II), the obtained results suggested that BNP
might even be more sensitive for estimating possible
cardiovascular complications in different forms of
SSc. Such results emphasize the role of laboratory
analyses in the treatment and follow-up of this partic-
ular group of patients. 
To further extend our previous findings, we ana -
lysed the levels of BNP according to the disease
extent and severity. According to our results, measur-
ing of BNP in SSc patients could also be useful in the
detection of disease severity (Figure 2). Intere stingly,
Elshamy et al. (42) demonstrated that NT-proBNP has
potential in estimating SSc severity. Our results
expand these previous findings by confirming that
BNP can also be used for the same purposes. Such
researches highlight the importance of cooperative
activities in the diagnostics and follow-up of complex
di seases.
Additionally (Table III), we found that BNP cor-
relates with age and disease duration but also with
Rodnan score, which is used as a sign of disease
severity and mortality in DSSc patients (41). These
results provide further strength to the proposed
hypothesis regarding the role of BNP as SSc type and
severity marker. It is known that the BNP is in negative
correlation with FAC. In our study, levels of BNP were
in significant positive correlations with FAC (Table III).
Right ventricle is the main source of circulating BNP,
and our results can be explained by the fact that the
right heart failure has not developed in our patients.
Our study had several limitations. First, the num-
ber of patients included in the study was small. The
reason for this is that SSc is a rare disease. Another
potential limitation of our study was that it included
the majority of patients with newly diagnosed SSc, but
still there was no development of RV myocardial dys-
function. Moreover, the data on BNP levels in the
control group are missing, so we could not compare
BNP concentrations between the SSc patients and
healthy individuals.
Conclusion
Notwithstanding the great progress in the treat-
ment of patients with systemic sclerosis, the percent-
age of cardiovascular involvement in these patients is
still relatively high.
Early detection of SSc in the period before sig-
nificant manifestation to certain organs or systems is
in the focus of many researchers. SSc is a lifelong dis-
ease and cannot be cured, but knowing that cardiac
dysfunction significantly worsens the prognosis, early
detection of cardiac complications and appropriate
therapy can influence its progress and improve the
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quality of life for patients. Our findings that BNP is
associated with the severity of the disease might sug-
gest that BNP is a more sensitive marker than
echocardiographic parameters for the evaluation of
systolic function. 
Given the obtained results, the laboratory de ter -
mi nation of BNP could be useful in differentiating
different forms of systemic sclerosis as well as in pre-
dicting the severity of the disease and future cardio -
vascular complications.
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